DGAP-Adhoc

WILEX AG plans rights issue using authorised capital - Seite 2

WILEX AG plans to use the expected gross proceeds from the rights issue of EUR 4,999,999.20 million mainly to finance the preclinical development of its proprietary ATAC candidate HDP-101 and to establish the GMP manufacturing process for Antibody Targeted Amanitin Conjugates (ATACs).

The new shares (ISIN DE000A2E4SX4 / WKN A2E/ 4SX) are to be admitted to trading on the regulated market of the Frankfurt Stock Exchange (Prime Standard) without the publication of an offering prospectus and are expected to begin trading on 15 May 2017.

For further details on the rights issue, please see the subscription offer expected to be published in the Federal Gazette (www.bundesanzeiger.de) on 25 April 2017 and on the website of WILEX AG (www.wilex.com).

Important notes

This ad hoc release does not constitute either an offer to sell or an invitation to buy securities. In particular, this document does not constitute an offer to sell securities or a solicitation of an offer to buy securities in the United States of America. The shares of WILEX AG (the "Shares") may not be offered or sold in the United States of America or to or for the account or benefit of "U.S. persons" (as defined in Regulation S under the U.S. Securities Act of 1933, as amended (the "Securities Act")), unless they have been registered or are exempt from registration under the Securities Act. The Shares have not been and will not be registered under the Securities Act. There will be no public offer of Shares in the United States of America.

+++ End of the Ad Hoc-Release +++

About WILEX

WILEX AG is a biopharmaceutical company based in Munich, Germany, that serves as a parent and holding company. The Company's research and development work is conducted by its subsidiary Heidelberg Pharma GmbH in Ladenburg. Heidelberg Pharma is the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary technology platform is being applied to develop the company's own therapeutic ATACs as well as in third-party collaborations to create a variety of ATAC candidates. The proprietary lead candidate HDP-101 is a BCMA-ATAC for multiple myeloma. WILEX's clinical assets MESUPRON^(R) and REDECTANE^(R) have been partnered, while RENCAREX^(R) is available for out-licensing and further development. WILEX is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at http://www.wilex.com/.